Clinical trialNCT06385236RecruitingPhase 4Interventional

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

SponsorUniversity of California, San DiegoEnrollment120Moderate to Severe Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kelan Tantisira, MD
University of California, San Diego
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic
Scottsdale, Arizona, United States
Deborah A Meyers, PhDGene R Bleecker, MD
Recruiting
University of California, San Diego
La Jolla, California, United States
Kelan Tantisira, MD →Praveen Akuthota, MD
Recruiting
Yale University
New Haven, Connecticut, United States
Geoffrey L Chupp, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Benralizumab →Dupilumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Feb 2024
Primary completion: 30 Jun 2027
Completion: 31 Jan 2028
Last update posted: 19 Aug 2024
Registered enrollment: 120
Registry id: NCT06385236

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.